Physician profile
Melanie Laforce
NPI 1952896342
$3,583.87
in general payments reported to CMS, 2019-2025
25 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,184 · 2022: $1,150 · 2023: $559 · 2024: $305 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.15 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $878.54 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $522.63 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $304.65 | 2021-2024 | Atacand, Farxiga |
| Abbott Laboratories | $294.23 | 2022-2025 | Cardiomems |
| Medtronic, INC. | $211.07 | 2022-2025 | Symplicity G3, Micra |
| Abiomed | $209.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.36 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $185.70 | 2021-2022 | |
| Daiichi Sankyo INC. | $173.54 | 2021-2023 | Injectafer |
| Amgen INC. | $137.22 | 2021-2024 | Repatha |
| Pfizer INC. | $86.97 | 2021-2024 | |
| Esperion Therapeutics, INC. | $60.26 | 2021-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $54.24 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.03 | 2021-2025 | Camzyos |
| Boston Scientific Corporation | $37.85 | 2023-2024 | Eluvia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $29.76 | 2021 | |
| Alnylam Pharmaceuticals INC. | $29.65 | 2024 | Amvuttra |
| Cardiovascular Systems INC. | $21.81 | 2021 | |
| Astellas Pharma US INC | $19.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.72 | 2022 | |
| Chiesi USA, INC. | $15.47 | 2022 | |
| Amarin Pharma, INC. | $13.88 | 2021 | |
| Novo Nordisk INC | $13.78 | 2024 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $11.44 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $10.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Laforce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.